share_log

Maxim Group Maintains Buy on Plus Therapeutics, Lowers Price Target to $12

Benzinga ·  May 3, 2023 10:11

Maxim Group analyst Jason McCarthy maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $30 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment